| 1 |
Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing |
|
| | Cátia F. Marques, Maria Matilde Marques, Gonçalo C. Justino | | | Pharmaceuticals. 2022; 15(9): 1039 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis |
|
| | Rolf Teschke, Gaby Danan | | | Medicines. 2020; 7(10): 62 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
RUCAM in Drug and Herb Induced Liver Injury: The Update |
|
| | Gaby Danan,Rolf Teschke | | | International Journal of Molecular Sciences. 2015; 17(1): 14 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Montelukast-loaded nanostructured lipid carriers: Part I Oral bioavailability improvement |
|
| | Arpana Patil-Gadhe,Varsha Pokharkar | | | European Journal of Pharmaceutics and Biopharmaceutics. 2014; | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Montelukast-Induced Adverse Drug Reactions: A Review of Case Reports in the Literature |
|
| | Gioacchino Calapai, Marco Casciaro, Marco Miroddi, Fabrizio Calapai, Michele Navarra, Sebastiano Gangemi | | | Pharmacology. 2014; 94(1-2): 60 | | | [Pubmed] [Google Scholar] [DOI] | | | 6 |
Current awareness: Pharmacoepidemiology and drug safety |
|
| | | | | Pharmacoepidemiology and Drug Safety. 2010; 19(2): i | | | [HTML Full text] [Google Scholar] [DOI] | |
|
